{"id":615,"date":"2026-03-10T01:23:05","date_gmt":"2026-03-10T01:23:05","guid":{"rendered":"https:\/\/euro-dmcrn.org\/2026\/?page_id=615"},"modified":"2026-03-10T01:34:48","modified_gmt":"2026-03-10T01:34:48","slug":"page-dyne","status":"publish","type":"page","link":"https:\/\/euro-dmcrn.org\/2026\/?page_id=615","title":{"rendered":"Page Dyne"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"615\" class=\"elementor elementor-615\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2d2444b e-con-full e-flex e-con e-parent\" data-id=\"2d2444b\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7a5e4e0 elementor-widget elementor-widget-heading\" data-id=\"7a5e4e0\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Industry Partner<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-706cd42 e-flex e-con-boxed e-con e-parent\" data-id=\"706cd42\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-83183e5 elementor-widget elementor-widget-image\" data-id=\"83183e5\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.dyne-tx.com\/\">\n\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"384\" src=\"https:\/\/euro-dmcrn.org\/2026\/wp-content\/uploads\/2026\/03\/DyneLogo_R_FINAL_FULL_COLOR_RGB-768x384.png\" class=\"attachment-medium_large size-medium_large wp-image-548\" alt=\"\" srcset=\"https:\/\/euro-dmcrn.org\/2026\/wp-content\/uploads\/2026\/03\/DyneLogo_R_FINAL_FULL_COLOR_RGB-768x384.png 768w, https:\/\/euro-dmcrn.org\/2026\/wp-content\/uploads\/2026\/03\/DyneLogo_R_FINAL_FULL_COLOR_RGB-300x150.png 300w, https:\/\/euro-dmcrn.org\/2026\/wp-content\/uploads\/2026\/03\/DyneLogo_R_FINAL_FULL_COLOR_RGB-1024x512.png 1024w, https:\/\/euro-dmcrn.org\/2026\/wp-content\/uploads\/2026\/03\/DyneLogo_R_FINAL_FULL_COLOR_RGB-1536x768.png 1536w, https:\/\/euro-dmcrn.org\/2026\/wp-content\/uploads\/2026\/03\/DyneLogo_R_FINAL_FULL_COLOR_RGB.png 1600w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4b828b0 e-con-full e-flex e-con e-child\" data-id=\"4b828b0\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6a2ce7b elementor-widget elementor-widget-text-editor\" data-id=\"6a2ce7b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><span lang=\"EN-US\">Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t <script type=\"text\/javascript\"> if (typeof(f_tFlgVISA) === typeof(Function))  \tf_tFlgVISA(null);  if (typeof(f_tFlgAllergia) === typeof(Function))  \tf_tFlgAllergia(null);  if (typeof(f_IDTipologia) === typeof(Function)) {  \tvar eObjTYPE = document.getElementById(\"id_IDTipologia\");  \tf_IDTipologia(eObjTYPE);  }  if (typeof(f_IDAttivita) === typeof(Function)) {  \tvar etFlgActivity = document.getElementById(\"id_IDAttivita\");  \tf_IDAttivita(etFlgActivity);  }  if (typeof(f_IDNazionalita) === typeof(Function)) {  \tvar etFlgNazionalita = document.getElementById(\"id_IDNazionalita\");  \tf_IDNazionalita(etFlgNazionalita);  }  if (typeof(f_IndFattIDNazione) === typeof(Function))  \tf_IndFattIDNazione(null);  <\/script>","protected":false},"excerpt":{"rendered":"<p>Industry Partner Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-615","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/euro-dmcrn.org\/2026\/index.php?rest_route=\/wp\/v2\/pages\/615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/euro-dmcrn.org\/2026\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/euro-dmcrn.org\/2026\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/euro-dmcrn.org\/2026\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/euro-dmcrn.org\/2026\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=615"}],"version-history":[{"count":5,"href":"https:\/\/euro-dmcrn.org\/2026\/index.php?rest_route=\/wp\/v2\/pages\/615\/revisions"}],"predecessor-version":[{"id":728,"href":"https:\/\/euro-dmcrn.org\/2026\/index.php?rest_route=\/wp\/v2\/pages\/615\/revisions\/728"}],"wp:attachment":[{"href":"https:\/\/euro-dmcrn.org\/2026\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}